Form 4 for OVID Ovid Therapeutics Inc.

Accepted 2026-03-02 00:00:00 ET · period of report 2026-02-23 · accession 0002036798-26-000004 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2026-03-02	2026-02-23	OVID	ALEXANDER MARGARET A.	Pres, CEO, Dir	S - Sale	$1.45	-11.7K	61.8K	-16%	-$16.9K
D	2026-03-02	2026-02-26	OVID	ALEXANDER MARGARET A.	Pres, CEO, Dir	A - Grant	$0.00	+1.44M	1.44M	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-02-23	S	D	11,656	$1.45	61,750	D	—	—	(F1) Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. (F2) The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.45 to $1.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
2	Derivative	Employee Stock Option (Right to Buy)	2026-02-26	A	A	1,435,000	$0.00	1,435,000	D	$1.65 · — to 2036-02-25	1,435,000 Common Stock	(F3) The shares subject to the stock option will vest in 48 equal monthly installments commencing on March 20, 2026, subject to the Reporting Person's continued services through each such date.